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Abstract 
Azithromycin (AZM), a 15-member macrolide antibiotic, possesses anti-inflammatory activ-
ity. Macrophages are important in innate and acquired immunity, and produce 
pro-inflammatory cytokines such as interleukin (IL)-12, which are composed of subunit p40 
and p35. The key function of IL-12 is the induction and maintenance of T-helper-1 re-
sponses, which is associated with the pathogenesis of chronic inflammatory diseases. We 
investigated the effect of azithromycin on IL-12p40 production in macrophages after 
lipopolysaccharide (LPS)/interferon (IFN)-γ stimulation. RAW264.7 macrophage cell line was 
pre-treated with vehicle or AZM, followed by the stimulation with LPS/IFN-γ. We measured 
IL-12 production by RT-PCR and ELISA. IL-12 transcriptional regulation was assessed by 
electrophoretic mobility shift assay and reporter assay. Phosphorylation of activator protein 
(AP)-1 and interferon consensus sequence binding protein (ICSBP) was assessed by im-
munoprecipitation using phosphotyrosine antibody, and immunoblotting using specific anti-
bodies against JunB and ICSBP. AZM reduced the induction of IL-12p40 by LPS/IFN-γ in a 
dose dependent manner. AZM inhibited the binding of AP-1, nuclear factor of activated T 
cells (NFAT), and ICSBP, to the DNA binding site in the IL-12p40 promoter. AZM also re-
duced LPS/IFN-γ-induced IL-12p40 promoter activity. Phosphorylation of JunB and ICSBP 
was inhibited by azithromycin-treatment in stimulated cells. In conclusion, AZM reduced 
IL-12p40 transcriptional activity by inhibiting the binding of AP-1, NFAT, and ICSBP to the 
promoter site. This may represent an important mechanism for regulating the 
anti-inflammatory effects of AZM in macrophages.   
Key words: azithromycin; macrophage; interleukin-12; activator protein-1; interferon consensus 
sequence binding protein. 
Introduction 
The macrolide antibiotics have been used for the 
treatment of chronic lung diseases. The low dose and 
long-term administration of erythromycin (EM) for 
patients with diffuse panbronchiolitis (DPB) has re-
portedly significant effects on the clinical conditions 
of those patients [1]. Similar therapeutic effects of an-
other 14-member macrolide, clarithromycin (CAM), 
have been reported in DPB patients [2]. The admini-
stration of azithromycin (AZM), a 15-member mac-
rolide, has also been observed to improve the clinical 
condition of patients with chronic lung diseases, such 
as DPB [3] and cystic fibrosis [4,5]. Int. J. Biol. Sci. 2009, 5 
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Although the precise mechanisms by which the 
macrolides benefit patients with chronic lung dis-
eases are not fully understood, circumstantial evi-
dence suggests that it is based on their 
anti-inflammatory activity, rather than their antibac-
terial activity. We have previously demonstrated that 
CAM modulates the immune system by reducing 
interleukin (IL)-8 production via the suppression of 
activator protein (AP)-1 activity in bronchial epithe-
lial cells [6], and that the 14-member macrolides, EM 
and CAM, enhance IL-10 signaling via signal trans-
ducer and activator of transcription-3/ suppressor of 
cytokine signaling-3 pathway after stimulation with 
lipopolysaccharide (LPS) [7]. 
Alveolar macrophages (AMs) are resident im-
mune cells with important roles in host defense and 
inflammation in the lung [8]. Invading pathogens are 
recognized via pathogen recognition receptors, such 
as the toll-like receptors (TLR), the scavenger recep-
tor, and the mannose receptor, and are phagocytosed 
by AMs [9]. These macrophages produce 
pro-inflammatory cytokines and chemokines, which 
accumulate and activate other inflammatory cells, 
such as neutrophils and T lymphocytes [10]. Thus, 
AMs’ production of these pro-inflammatory cyto-
kines is thought to be tightly linked to the severity of 
lung inflammation. 
In treatment of chronic inflammatory diseases, 
the suppression of excess inflammatory cytokines is a 
potent therapeutic target. Based on the above men-
tioned action, macrolide antibiotics are one of the 
candidates for the treatment of chronic inflammatory 
diseases. AZM also possesses anti-inflammatory ac-
tivity; AZM has been shown to reduce the production 
of the pro-inflammatory cytokines IL-12 and IL-6, and 
increase the production of the anti-inflammatory cy-
tokine IL-10 in macrophage cell lines after stimulation 
with a combination of LPS and interferon (IFN)-γ 
(LPS/IFN-γ) [11]. 
IL-12 is a heterodimeric cytokine produced by 
macrophages and dendritic cells. The key roles of 
IL-12 are to promote the differentiation of naive T 
cells into T-helper-1 (Th1) cells, and to induce a Th1 
immune response to bacteria, or their cell wall com-
ponents, such as LPS. Thus, IL-12 is an important cy-
tokine for cell-mediated immunity and host defense 
[12]. Over-expression of IL-12 is associated with the 
pathogenesis of chronic inflammatory diseases, such 
as Crohn’s disease, and rheumatoid arthritis [13]. 
IL-12p40 and p35 are encoded on separate genes 
that form the biologically active p70 heterodimer. The 
p40 is not only a component of IL-12, but also that of 
IL-23. The p40 is only induced in cells that produce 
bioactive IL-12, while p35 gene is constitutively ex-
pressed in many cell types. IL-12 production is 
strongly induced by intracellular bacteria and bacte-
rial products. Therefore, the transcription of IL-12 is 
dependent on the activity of the p40 promoter. Ele-
ments of this promoter include the AP-1 binding site 
(from -81 to -75) [14], and the interferon consensus 
sequence binding protein (ICSBP)/nuclear factor of 
activated T-cells (NFAT) heterodimer binding site 
(from -68 to -54) [15], both of which are functionally 
important for p40 promoter activation following 
LPS/IFN-γ stimulation. Although ICSBP cannot bind 
to this promoter element by itself, ICSBP het-
erodimerized with NFAT can [15]. 
On this basis, we hypothesized that AZM sup-
presses IL-12 production by repressing the activity of 
the IL-12p40 promoter. We investigated IL-12 expres-
sion and IL-12 promoter activity in macrophage cell 
lines pretreated with AZM upon the stimulation of 
LPS/IFN-γ. 
Materials and Methods 
Cell growth and Cell viability 
 Effects of Azithromycin on cell proliferation and 
viability were evaluated with the alamarBlue assay 
(BioSource International, Camarillo, CA). RAW264.7 
cells (ACTT number TIB-71) were cultured at 37 °C 
for 0 - 72 h in 96-well plastic plates at a density of 
4,000 cells/well in 20 μl of alamerBlue dye solution in 
180  μL DMEM in the presence or absence of AZM 
(Pfizer, Inc. New York, NY) (0.1, 1.0, 10, and 20 
μg/mL). The optical density (OD) of the culture me-
d i u m  w a s  m e a s u r e d  a t  5 9 5  n m  w i t h  s p e c t r o p h o -
tometoric microtiter plate reader (Model 450; Bio-Rad 
Laboratories, Inc., Herculs, CA) at 0, 1, 4, 6, 8, 24, 36, 
48, 60, and 70 h. 
Pre-treatment with AZM and stimulation with 
LPS/IFN-γ 
 RAW264.7 cells were seeded onto 6 cm dishes at 
1×106 cells/dish and were pre-treated with vehicle 
(absolute ethanol) and AZM at 0, 1, 10 and 20 μg/mL, 
for 24 h. In all experiments, the final concentration of 
ethanol in culture medium was 0.5%. Cells were 
stimulated with LPS (100 ng/mL; Sigma-Aldrich, UK, 
L9143, LPS from Escherichia coli O111:448, purified by 
phenol extraction) and IFN-γ (400 U/mL; R&D Sys-
tems, Minneapolis, MN, USA) for 3 h (for total RNA 
isolation, nuclear protein and cytoplasmic protein 
preparations), or 8 h (for supernatant collection). 
Control cells were not stimulated with LPS/IFN-γ. 
Reverse transcription (RT)-PCR 
Total RNA from cells was extracted by RNeasy 
Kit (Qiagen, Valencia, CA, USA). RT was conducted Int. J. Biol. Sci. 2009, 5 
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using SuperScript III reverse transcriptase (Invitrogen 
Corp., Carlsbad, CA, USA). cDNA was amplified by 
Taq DNA polymerase (Platinum Taq DNA poly-
merase, Invitrogen) with specific primers: for 
IL-12p40 (forward; GTG AAG CAC CAA ATT ACT 
CCG G, reverse; GCT TCA TCA TCT GCA AGT TCT 
TGG G, 30 cycle), for GAPDH (forward; ACTC CAC 
TCA CGG CAA ATT CAA CGG, reverse; AGG GGC 
GGA GAT GAT GAC CC, 25 cycle), and for β-actin 
(forward; GTG GGC CGC TCT AGG CAC CAA, re-
verse; CTC TTT GAT GTC CAC GCA CGA TTT C, 25 
cycle) [16]. PCR products were electrophoresed in 
1.5% agarose gels containing ethidium bromide and 
visualized digitally with a UV illuminator (ATTO 
Bioscience, Tokyo, Japan). Band intensities were 
semi-quantified using computer software (Lane Ana-
lyzer 3.0; ATTO Bioscience, Tokyo, Japan). 
ELISA 
IL-12/IL-23p40 concentrations were measured 
using a sandwich ELISA kit (R&D Systems, Minnea-
polis, MN, USA) according to the manufacturer’s 
protocol. Briefly, 50 μL supernatants were added into 
flat-bottom 96-well microtiter plates pre-coated with 
antibody against p40, followed by incubation for 2 h 
at room temperature. Plates were washed four times, 
followed  by the addition of 100 µl/well antibody 
against p40 conjugated with horseradish peroxidase. 
After 2 hours of incubation, plates were washed four 
times with wash buffer. Then, the substrate solution 
was added, and the plates were incubated for 30 min 
at room temperature. The reaction was terminated 
with stop solution. Optical densities of plates were 
read at 450 nm in a microplete reader (Bio-Rad Labo-
ratories). 
Electrophoretic mobility shift assays (EMSA) 
  Nuclear extracts of RAW264.7 cells, with or 
without pre-treatment with AZM, were obtained, as 
described previously [17]. The activities of AP-1 and 
NFAT/ICSBP were assessed by EMSA with consen-
sus oligonucleotides of IL-12p40 (AP-1: GAG ACT 
AGT CAG TTT, and ICSBP/NFAT: TCA GTT TCT 
ACT TTG GGT TTC CAT CAG AA). We used an 
EMSA kit (LightShift Chemiluminescent, Pierce Bio-
technology, Inc., Rockford, IL, USA) with biotin 
end-labeled DNA probes instead of radioactive 
probes. Nuclear protein (4 μg) was incubated with 
labeled probes for 20 min at room temperature. The 
mixture was electrophoresed on a polyacrylamide gel 
and transferred to a nylon membrane. The biotin 
end-labeled DNA was detected according to the 
manufacturer’s protocol. Band specificity was deter-
mined with competition experiments using a molar 
excess of unlabeled consensus oligonucleotides of 
AP-1, or ICSBP/NFAT that were added to the nuclear 
extracts before the addition of labeled probes. 
Plasmids and site-directed mutagenesis 
 The murine IL-12p40 promoter, from the -101 
to +55 region, was amplified from genomic DNA iso-
lated from the mouse tail by PCR using an upstream 
primer containing the KpnI restriction site (GCC GGG 
TAC CTT TCA GTG TTG CAA TTG AGA CTA GTC 
AGT T) and a downstream primer containing the 
XhoI site (ACT TCT CGA GTT GCT TTG CTG CGA 
GCT GCC TGG TCT GAT GT). This was inserted into 
the luciferase reporter vector pGL4 (Promega Corp., 
Madison, WI, USA). The 3-bp mutants of AP-1, ICSBP 
and NFAT were generated using a site-directed 
mutagenesis kit (QuickChange II Site-Directed 
Mutagenesis Kit; Stratagene, La Jolla, CA, USA) using 
oligonucleotide primers, AP-1 (forward; GTT GCA 
ATT GAG ACT CTG CAG TTT CTA CTT TGG, re-
verse; CCA AAG TAG AAA CTG CAG AGT CTC 
AAT TGC AAC), ICSBP (forward; GAG ACT AGT 
CAG TTG ACA CTT TGG GTT TCC A, reverse; TGG 
AAA CCC AAA GTG TCA ACT GAC TAG TCT C), 
and NFAT (forward; GTC AGT TTC TAC TTT GTA 
GTT CCA TCA GAA AGT TC, reverse; GAA CTT 
TCT GAT GGA AAT CCA AAG TAG AAA CTG 
AC). 
Transfection and reporter gene assays 
  Reporter plasmids containing the murine 
IL-12p40 promoter (from -101 to +55) or mutated 
forms of AP-1, ICSBP and NFAT, were transfected 
into RAW264.7 cells by Nucleofector (Amaxa Inc., 
Walkersville, USA). RAW264.7 cells were 
co-transfected with 2 μg of the pGL4/IL-12p40 pro-
moter vector and 0.1 μg of the phRL-TK vector 
(Promega Corp., Madison, WI, USA). Twenty-four 
hours after transfection, cells were treated with vehi-
cle or AZM (1.0 and 20 μg/mL) for 24 h, and subse-
quently stimulated with LPS/IFN-γ f o r  2 4  h .  C e l l s  
were lysed with lysis buffer, and luciferase activity 
was assayed using the Dual Luciferase Assay System 
(Promega Biosciences, San Luis Obispo, CA, USA). 
First, firefly luciferase activities were assessed by a 
luminometer (MiniLumat LB 9506, Berthold, Ger-
many). Then, after the addition of Stop & Glo solu-
tion (Promega), Renilla luciferase activities (an inter-
nal control for transfection efficiency) were also 
measured by by a luminometer. 
Western blotting for JunB, ICSBP and NFAT 
After LPS/IFN-γ stimulation, cytoplasmic and 
nuclear proteins were extracted from the 
AZM-treated RAW264.7 cells using the NE-PER nu-Int. J. Biol. Sci. 2009, 5 
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clear and cytoplasmic extraction reagents kit (Thermo 
Fisher Scientific, Rockford, IL, USA). 
Twenty microgram of cytoplasmic protein or 5 
μg of nuclear protein were blotted onto a PVDF 
membrane (Amersham, Piscataway, NJ, USA). The 
membranes were blocked with milk, and treated with 
JunB antibody (1:200 dilution; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), ICSBP antibody (1:200 
dilution; Santa Cruz Biotechnology), or NFATc1 an-
tibody (1:200 dilution; Santa Cruz Biotechnology), 
followed by horseradish peroxidase-conjugated, 
anti-rabbit IgG (1:3000 dilution; Santa Cruz Biotech-
nology). These proteins were detected using the ECL 
plus system (Amersham), and exposed on Fuji X-ray 
film. 
Immunoprecipitation and immunoblotting 
  Nuclear proteins were extracted from 
RAW264.7 cells pre-treated with vehicle or AZM (1.0 
and 20 μg/mL) followed by stimulation with 
LPS/IFN-γ for 3 h. Immunoprecipitation was per-
formed with 200 μg nuclear protein. Nuclear proteins 
were diluted into RIPA buffer containing both prote-
ase and phosphatase inhibitors [18], and incubated 
with 1 μL of phosphotyrosine antibody (4G10, Milli-
pore, Bedford, MA, USA) for 4 h at 4 °C, followed by 
incubation with 15 μL of 50% sepharose G protein 
beads for 1 h (Sigma-Aldrich, UK). Beads were 
washed three times with RIPA buffer (without SDS), 
and proteins were eluted by boiling in SDS sample 
buffer, separated on 12% SDS-PAGE, and transferred 
onto a nitrocellulose membrane. Blots were probed 
with antibody against JunB (1:200 dilution; Santa 
Cruz Biotechnology) or against ICSBP (1:200 dilution; 
Santa Cruz Biotechnology), and protein signals were 
detected with the ECL plus system (Amersham) for 
JunB, and Western Breeze (Invitrogen Corp., Carls-
bad, CA, USA) for ICSBP. 
Statistical analysis 
Multiple comparisons were performed by one 
way ANOVA followed by the Stu-
dent-Newman-Keuls method. Results are expressed 
as the mean ± SD. Statistical significance was taken to 
be P < 0.05. Statistical analyses were done using 
computer software (StatView 5.1, SAS Institute, Inc., 
Cary, NC, USA).   
Results 
Effects of AZM on the cell viability of RAW 
264.7cells 
  First, we assessed the influence of AZM on cell 
growth and viability by alamerBlue assay. Neither 
lower (0.1 and 1.0 μg/mL) nor higher (10 and 20 
μg/mL) concentrations of AZM affected the prolif-
eration and viability of RAW 264.7 cells (Figure 1). In 
microscopic observations, RAW 264.7 cells grew to 
up to 90-100% confluence in a 96-well culture plate 
after incubation for 72 h, no morphologic changes 
were observed in resting cells or AZM-treated cells. 
Nevertheless, the question remains whether there is 
broad-based inhibition of transcriptional activity be-
cause the cells are metabolically affected by the AZM 
treatment. We also examined the expression of 
β-actin, a cytoskeleton protein, which is widely used 
as internal control gene in RT-PCR. The expression 
levels of GAPDH/β-actin mRNAwere not changed 
by AZM treatment for 72 h (Relative expression: ve-
hicle 1.00 ± 0.12, AZM 1.0 μg/mL 1.12 ± 0.24, and 
AZM 20 μg/mL 0.98 ± 0.10, p = 0.94, n = 5 in each 
group). 
 
 
 
Figure 1. Effect of azithromycin (AZM) on 
RAW264.7cell growth and cell viability.  Cells were 
cultured with alamarBlue dye solution in absence or pres-
ence of AZM (0.1, 1.0, 10, and 20 μg/ml) for 72 h, and the 
optical density (OD) at 595 nm was measured at the indi-
cated time points. Proliferation and viability of RAW264.7 
cells were determined in relation to growth curve, based on 
the measurement of OD at each time point. Data are mean 
value of six independent experiments. 
 
AZM inhibited IL-12p40 gene expression induced 
by LPS/IFN-γ 
  IL-12p40 gene expression was not detected in 
the control cells (treated with vehicle only), or AZM 
treated RAW264.7 cells not stimulated with 
LPS/IFN-γ (Figure 2A). Cells stimulated with 
LPS/IFN-γ for 3 h showed elevated IL-12p40 gene 
expression by RT-PCR. The LPS/IFN-γ-induced 
IL-12p40 gene expression was inhibited by Int. J. Biol. Sci. 2009, 5 
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pre-treatment with AZM in a dose dependent manner 
(Figure 2A). 
 
Figure 2. The production of IL-12p40 in RAW264.7 
macrophage cells pre-treated with azithromycin 
(AZM) and stimulated with LPS/IFN-γ. (A) 
  RAW264.7 cells were pre-treated with AZM (1.0 and 
20 μg/mL) for 24 h, and stimulated with LPS/IFN-γ for 3 h. 
Gene expression of IL-12p40 was evaluated by RT-PCR. 
The expression of IL-12p40 gene was increased by 
LPS/IFN-γ stimulation compared with the control cells. This 
increased expression was inhibited by AZM in a dose de-
pendent manner. (B)  The  p40  protein  levels  were 
measured by ELISA in the supernatants of cells pre-treated 
with vehicle, or AZM, for 24 h, followed by stimulation with 
LPS/IFN-γ for 8 h. The p40 protein levels were increased by 
LPS/IFN-γ, and these levels were significantly reduced by 
pre-treatment with AZM. Each group comprised five in-
dependent experiments. Data are expressed as the mean ± 
SD. 
# P < 0.05 vs. vehicle vehicle-pretreatment followed by 
LPS/IFN-γ stimulation, 
## P < 0.01 vs. vehicle-pretreatment 
followed by LPS/IFN-γ stimulation. N.D. indicates that the 
expression was not detected. 
AZM reduced the production of p40 protein in-
duced by LPS/IFN-γ 
The levels of p40 protein in the supernatant 
from cells stimulated with LPS/IFN-γ for 8 h were 
significantly elevated, compared with those of un-
stimulated cells. The LPS/IFN-γ-induced p40 produc-
tion was inhibited by pre-treatment with AZM in a 
dose dependent manner (Figure 2B). 
AZM inhibited interactions between transcrip-
tion factors (AP-1, ICSBP, and NFAT) and 
IL-12p40 promoter elements 
 EMSA was used to assess the effect of AZM on 
DNA-protein interactions in the IL-12p40 promoter. 
Using the AP-1 probe, an increase in DNA-nuclear 
protein complexes was observed in RAW264.7 cells 
stimulated with LPS/IFN-γ (Figure 3A, lane 
2), compared with unstimulated cells (Figure 3A, lane 
1). This increase in DNA-protein complex was re-
duced by co-incubation with an excess of unlabeled 
AP-1 oligonucleotide (Figure 3A, lane 4), and by 
pre-treatment with AZM (Figure 3A, lane 3). Simi-
larly, using the ICSBP/NFAT probe, an increase in 
DNA-nuclear protein complexes was observed in 
LPS/IFN-γ stimulated cells (Figure 3B, lane 
6) compared with unstimulated cells (Figure 3B, lane 
5), and this increase was inhibited by co-incubation 
with an excess of unlabeled ICSBP/NFAT oligonu-
cleotide (Figure 3B, lane 8), and pre-treatment with 
AZM (Figure 3B, lane 7). 
AZM reduced IL-12p40 promoter activity fol-
lowing LPS/IFN-γ stimulation 
  To investigate whether AZM affected promoter 
activity by changing the affinity between the binding 
elements in the IL-12p40 promoter and transcription 
factors, we performed an assay using a reporter 
plasmid with a 3-bp mutation in the AP-1 (-79 to -77), 
ICSBP (-71 to -69), or NFAT (-62 to -60) binding sites 
(Figure 4A). AZM decreased IL-12p40 reporter activ-
ity of LPS/IFN-γ treated cells in a dose dependent 
manner (Figure 4B). Mutation of the AP-1, ICSBP or 
NFAT sites in the IL-12p40 promoter resulted in de-
creased luciferase signals after stimulation with 
LPS/IFN-γ. Furthermore, these mutations abrogated 
the inhibitory effects of AZM on LPS/IFN-γ-induced 
promoter activities (Figure 4B).   
AZM inhibited phosphorylation of JunB and 
ICSBP. 
  The AP-1 binding motif in the IL-12p40 pro-
moter is reportedly associated with JunB, c-Jun or 
c-Fos [14]. Among these components of AP-1, phos-
phorylation of JunB is related to binding to DNA, and Int. J. Biol. Sci. 2009, 5 
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to the expression of AP-1 regulated genes [19]. Tyro-
sine phosphorylation of ICSBP reportedly increases 
the affinity of protein-DNA interactions [20]. Stimu-
lation with LPS/IFN-γ elevated the protein levels of 
JunB and ICSBP in the nuclear fraction (Figure 5A 
and 5C, upper panel lane 3), and this increase was not 
affected by pre-treatment with AZM (Figure 5A and 
5C, upper panel lane 4). Stimulation with LPS/IFN-γ 
elevated the levels of phosphorylated JunB and 
ICSBP in the nuclear fraction (Figure 5B and 5D, lane 
7), and these elevated levels were decreased by 
pre-treatment with AZM (Figure 5B and 5D, lane 8). 
  NFAT levels were not increased after stimula-
tion with LPS/IFN-γ (data not shown). Levels of nu-
clear NFAT in cells following LPS/IFN-γ stimulation 
were not increased compared with those of unstimu-
lated cells (data not shown). AZM did not change the 
level of nuclear NFAT (data not shown). 
 
 
Figure 3. Azithromycin (AZM) inhibited the association of 
activator protein (AP)-1 and interferon consensus sequence 
binding protein (ICSBP)/ nuclear factor of activated T-cells 
(NFAT) with DNA-binding sites in the IL-12p40 promoter. 
Effect of AZM on AP-1 binding activity for the IL-12p40 promoter was 
assessed by EMSA. Nuclear extracts were obtained from resting 
RAW264.7 cells (lane 1), cells pre-treated with vehicle followed by 
stimulation with LPS/IFN-γ (lane 2), and from cells pre-treated with 
AZM (20 μg/mL) followed by stimulation with LPS/IFN-γ (lane 3). In 
lane 4, nuclear extract from cells pre-treated with vehicle followed by 
stimulation with LPS/IFN-γ were treated with excess cold probe. 
AP-1-DNA binding activity was enhanced by LPS/IFN-γ stimulation. 
Enhanced binding was inhibited by pre-treatment with AZM. Specific 
competition with cold probe eliminated the DNA-nuclear protein 
complex band. Effect of AZM on ICSBP/NFAT binding activity for 
IL-12p40 promoter was assessed by EMSA. Nuclear extracts were 
obtained from resting RAW264.7 cells (lane 5), cells pre-treated with 
vehicle followed by stimulation with LPS/IFN-γ (lane 6), and from cells 
pre-treated with AZM (20 μg/mL) followed by stimulation with 
LPS/IFN-γ (lane 7). In lane 8, nuclear extract from cells pre-treated with 
vehicle followed by stimulation with LPS/IFN-γ were treated with 
excess cold probe. ICSBP/NFAT DNA binding activity was enhanced 
by LPS/IFN-γ stimulation. Enhanced binding was inhibited by 
pre-treatment with AZM. Specific competition with cold probe 
eliminated the DNA-nuclear protein complex band. Representative 
images from three independent experiments are shown. “+” indicates 
the presence of pretreatment of AZM, stimulation of LPS/IFN-γ or cold 
probe in experiment of each lane. “–” indicates the absence of pre-
treatment of AZM, stimulation of LPS/IFN-γ or cold probe in ex-
periment of each lane. 
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Figure 4. Inhibition of IL12-p40 promoter activity by azithromycin (AZM) in RAW264.7 macrophage cells. 
(A)   Three-base pair substitution mutants were created from -79 to -77 [activator protein (AP)-1 binding site], -71 to -69 
[interferon consensus sequence binding protein (ICSBP) binding site], and -62 to -60 [nuclear factor of activated T-cells 
(NFAT) binding site], in the IL-12p40 promoter. (B)  RAW264.7 cells were co-transfected with wild-type, or each mutant 
reporter plasmid, and phRL-TK reporter plasmid. After 24 h, cells were incubated with vehicle or AZM for 24 h, and 
stimulated with LPS/IFN-γ for 24 h. Luciferase activity was normalized to phRL-TK activity, and results expressed as a 
percentage of promoter activity compared with LPS/IFN-γ stimulation for wild-type -101 to +55 IL-12p40 pro-
moter-luciferase plasmid (100%). Stimulation with LPS/IFN-γ markedly increased the luciferase activity in the wild-type 
IL-12p40 promoter, and AZM significantly reduced LPS/IFN-γ-induced IL-12p40 promoter activity in a dose dependent 
manner. Each mutation of AP-1, ICSBP, and NFAT repressed LPS/IFN-γ-induced promoter activity, and abrogated the 
inhibitory effects of AZM on IL-12p40 promoter activity. Five independent experiments in each group, 
## P < 0.01 vs. 
wild-type + LPS +IFN-γ. Int. J. Biol. Sci. 2009, 5 
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Figure 5. Azithromycin (AZM) inhibited phosphorylation of JunB and interferon consensus sequence 
binding protein (ICSBP). Nuclear and cytoplasmic fractional proteins were prepared from RAW264.7 cells stimulated 
with LPS/IFN-γ for 3 h in the presence of vehicle or AZM. Stimulation of LPS/IFN-γ elevated JunB and ICSBP protein levels 
in nuclear fractions (A and C, upper panel lane 3). However, AZM did not reduce the protein levels of JunB and ICSBP (A and 
C, upper panel lane 4). Nuclear proteins were immunoprecipitated with an antibody against phosphotyrosine. Immuno-
precipitated proteins were immunoblotted with antibody against JunB and ICSBP. The phosphorylation of JunB and ICSBP 
was enhanced by stimulation of LPS/IFN-γ (B and D, lane 7). This enhanced phosphorylation was abrogated by AZM 
treatment (B and D, lane 8). 
 
Discussion 
  We have shown that pre-treatment with AZM 
reduces the production of IL-12 in LPS/IFN-γ stimu-
lated macrophages (Figure 2). Murphy et al. demon-
strated that AZM suppressed IL-12 production in 
AMs [11], however, no mechanism was proposed. 
The present study demonstrates one of the mecha-
nisms by which AZM suppresses IL-12 in macro-
phages. 
  IL-12 transcriptional regulation reportedly oc-
curs via the IL-12p40 promoter through its interaction 
with transcription factors, such as AP-1, ICSBP and 
NFAT [14,15]. In the present study, AZM was shown 
to inhibit binding of these transcriptional factors to 
their DNA binding-sites (Figure 3). IL-12p40 pro-
moter activity was inhibited by AZM in a dose de-
pendent manner (Figure 4B). In addition, mutation of 
AP-1, ICSBP or NFAT in this promoter region abro-
gated the inhibitory effect of AZM (Figure 4B). We 
also showed that treating cells with AZM prior to 
stimulation with LPS/IFN-γ, reduced the levels of 
active (tyrosine phosphorylated) JunB and ICSBP 
produced (Figure 5B & 5D). It is likely that the in-
hibitory effect of AZM on the phosphorylation of 
JunB and ICSBP is one of the key mechanisms in the 
suppression of IL-12 production by macrophages. 
 Although there is no detection of IL-12p40 gene 
expression in vehicle-treated cells, basal levels of p40 
protein are detected in the supernatant (Figure 2). Int. J. Biol. Sci. 2009, 5 
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This means that the gene expression of IL-12p40 in 
untreated cells is under the detection limit in this 
PCR system. As shown in Figure 5B & 5D, vehi-
cle-treated cells exhibit detectable levels of active, 
tyrosine-phosphorylated JunB and ICSBP, but the 
levels of tyrosine-phosphorylated JunB and ICSBP in 
unstimulated cells were significantly low, compared 
with those of LPS/IFN stimulated cells (Figure 5B & 
5D). These phosphorylated JunB and ICSBP in un-
stimulated cells may be implicated in the detectable 
level of IL-12p40 protein in unstimulated cells. 
  N F A T  u s u a l l y  e x i s t s  i n  p h o s p h o r y l a t e d  f o r m ,  
and resides in the cytoplasm in the rest condition. 
Upon the stimulation, NFAT is dephosphorylated, 
and is translocated into the nucleus [21]. In the pre-
sent study, the nuclear protein level of NFAT in cells 
stimulated with LPS/IFN-γ was not changed by 
AZM. Because the heterodimerized complex of 
ICSBP/NFAT reportedly binds to the IL-12p40 pro-
moter and activates it [15], a reduction in the level of 
NFAT is not necessarily associated with the reduction 
of IL-12 p40 promoter activity by AZM in LPS/IFN-γ 
stimulated cells. 
The mechanism for repressing the phosphoryla-
tion of JunB and ICSBP is still unclear. We and other 
investigators have previously demonstrated that 
14-member macrolides enhanced the production of 
anti-inflammatory cytokine IL-10 [7,11]. It is reported 
that IL-10 suppresses the phosphorylation of AP-1 
[22]. Taken together, it may be possible that AZM 
enhances the production of IL-10, which suppresses 
the phosphorylation of JunB and ICSBP. 
Another possible explanation for this suppres-
sion of IL-12 is repression of nuclear factor (NF)-κB 
pathway that is a key transcription factor related to 
the expression of pro-inflammatory cytokines. In our 
preliminary experiment, we examined the expression 
of TLR4 in the AZM-pretreated cells upon the stimu-
lation of LPS/IFN-γ, and observed that the expression 
of TLR4 remained unchanged (data not shown). 
However, it has already been reported that AZM 
suppressed NF-κB pathway [23]. Thus, it is likely that 
the modulation of NF-κB signaling is in-
volved in the mechanisms for the suppres-
sion of IL-12 by AZM. In Figure 6, we 
summarized the intracellular pathways 
that lead to the production of IL-12p40 and 
the mechanisms of AZM to inhibit the ex-
pression of IL-12p40 [14,15,23-26]. 
 
 
Figure 6. Diagrammatic representation 
of intracellular pathways that lead to the 
production of IL-12p40 and the mecha-
nisms of azithromycin (AZM) to inhibit 
the expression of IL-12p40 upon the 
stimulation of LPS/IFN-γ. (A)   Inflamma-
tory stimulation leads to the activation of vari-
ous signal transduction cascades in cells. Binding 
of LPS and toll-like receptor (TLR)-4 activates 
NF-κB. Soon after occurring LPS/TLR-4 signaling, 
IKB is degraded in this process. Subsequently, 
NF-κB translocates into the nucleus, and binds 
to its binding motif in promoter region of 
IL-12p40. Moreover, LPS/TLR-4 signaling results 
in the activation of MAPK pathway, which leads 
to the phosphorylation of activator protein 
(AP)-1, such as JunB. Phosphorylated AP-1 binds 
to its binding motif in the promoter. Binding of 
IFN-γ and its receptor activates JAK-STAT 
pathways, and other pathways, such as PI3K and 
Pyk2. Activated STAT1 phosphorylates ICSBP. 
In this cellular activation process, calcium influx 
is induced, and elevated intracellular concen-
tration of calcium activates calcineurin. Then, Int. J. Biol. Sci. 2009, 5 
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NFAT is dephosphorylated by activated calcineurin, and 
subsequently translocates into the nucleus. NFAT het-
erodimerizes with ICSBP, and this heterodimer binds to the 
binding motif in promoter. Activated PI3K and Pyk2 also 
activate the MAPK pathway. (B)   In the presence of 
AZM, the phosphorylation of ICSBP and JunB is inhibited. 
This inhibition results in the reduced binding capacity of 
ICSBP/NFAT and JunB to their DNA binding motif in the 
IL-12p40 promoter, and IL-12p40 gene expression is sup-
pressed. It was also reported that AZM inhibits NF-κB 
pathway by reducing the degradation of IKB (reference 23). 
  Abbreviations: ICSBP, interferon consensus sequence 
binding protein; IKB, inhibitor of κB; JAK, Janus kinase; 
MAPK, mitogen activated protein kinase; MyD88, myeloid 
differentiation primary response gene 88; NFAT, nuclear 
factor of activated T-cells; NF-κB, nuclear factor-κB; PI3K, 
phosphatidylinositol 3-kinase, Pyk2, calcium-dependent 
tyrosine kinase; STAT1, signal transducer and activator of 
transcription 1; TAK1, transforming growth fac-
tor-beta-activated kinase 1; TRA6, TNF recep-
tor-associated factor 6. 
 
IL-12 plays an important role in promoting a 
Th1 response while suppressing a Th2 response. 
IL-12-deficient mice and IL-12 neutralizing antibodies 
reportedly suppress Th1 responses, and reduce pro-
tection against intracellular pathogens [12]. IL-12 
knockout mice exhibit limited inflammatory reactions 
[27], whereas IL-12 p40 over-expression is related to 
chronic inflammatory and autoimmune diseases 
[13,28]. Th1 cytokine-induced inflammation is associ-
ated with chronic lung diseases. The levels of IL-12 in 
exhaled breath condensate of COPD patients are ele-
vated, compared with those of control subjects [29]. 
In addition, CD8 positive T lymphocytes, Th1 cyto-
kine-producing cells, are increased in the lung of 
COPD patients [30,31]. Taken together, the balance of 
Th1/Th2 balance in the lung of COPD patients seems 
to be shifted toward Th1 dominant. Furthermore, Th1 
cytokines are increased in the lung of DPB patients 
[32]. 
Accumulating evidences suggest that use of 
macrolides has many beneficial effects on such 
chronic lung diseases. Seemungal and colleagues re-
ported that administration of long-term erythromycin 
(250 mg/day) reduced the exacerbation in COPD pa-
tients [33]. Clarithromycin prevents the development 
of pulmonary emphysema in cigarette smoking mice 
[34]. Long-term and low dose administration of 
14-member macrolide antibiotics is an effective 
treatment for DPB [1,2]. 
Cystic fibrosis is an autosomal recessive disease 
primarily affecting the lungs. To date, any curative 
treatment for this disease has not been established. 
The pathophysiology of cystic fibrosis lung disease is 
related to the abnormal cystic fibrosis transmembrane 
receptor present in the apical cell membrane of air-
way epithelial cells [35]. Dysfunction of bronchial 
epithelial cells creates an inflammatory milieu in air-
ways, causing damage to the airway system [35]. Be-
cause chronic airway inflammation is deeply in-
volved in the pathophysiology of cystic fibrosis, AZM 
is hoped to be as a part of the standard maintenance 
therapy against this disease [35]. In fact, the admini-
stration of AZM to the murine model of cystic fibrosis 
attenuates the accumulation of AMs after 
LPS-induced inflammation [36]. 
In these chronic lung diseases, excess 
pro-inflammatory cytokines play harmful roles for 
the deterioration of disease severity. Therefore, the 
attenuation of excess pro-inflammatory cytokines is a 
potent therapeutic target for such diseases. Indeed, 
pro-inflammatory cytokines, such as TNF-α, IL-1β, 
IL-6 and IL-8, are known to be suppressed by AZM 
[23,37]. Because IL-12 plays key roles in Th1-related 
diseases, the attenuation of IL-12 production by AZM 
may also contribute to improve the condition of 
chronic lung diseases. Furthermore, because AZM 
inhibits the production of IL-12p40 protein, it is sug-
gested that AZM also attenuates the expression of 
IL-23, the cytokine composed of IL-12p40 and 
IL-23p19 [38]. IL-23 plays key roles in autoimmune 
diseases and graft rejection through the activation of 
Th-17 cells [38]. Therefore, AZM might have some 
beneficial effects on autoimmune diseases and graft 
rejection. 
Furthermore, the colonization of bacteria or 
fungus is frequently observed in chronic airway dis-
eases. Thus, excess immune suppression is risk for 
the growth of these pathogens. Corticosteroid and 
immune suppressants, such as cyclosporine, cause 
strong immune suppression. Long term administra-
tion of these medicines sometimes causes respiratory 
infection, such as pneumonia. However, immune 
modulation of macrolide antibiotics is not so strong 
that, to our best knowledge, long term macrolide 
therapy does not result in the deterioration of infec-
tions. 
Macrolide antibiotics are suitable in the treat-
ment of respiratory tract infections due to their good 
penetration into lung tissue. Levels of AZM after oral 
administration of 500 mg reach 2.18 μg/mL in epithe-
lial lining fluid, and 23.0 μg/mL in AMs [39]. Thus, 
the dose of AZM used in this study was comparable 
with that achieved therapeutically. 
  In conclusion, AZM reduced IL-12 p40 tran-
scriptional activity by inhibiting the binding of AP-1, 
NFAT, and ICSBP to this promoter site. This may Int. J. Biol. Sci. 2009, 5 
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represent a mechanism for the regulation of the 
anti-inflammatory effects of AZM in macrophages. 
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